Norgine

Company snapshot

Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with more than €500 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across their core markets of Western Europe, Australia, and New Zealand. Today’s Norgine is a nimble, innovative, and high-performing company that has been transformed by a

• 2 approved product(s) across US/EU regulatory metadata.
• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Norgine. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Norgine.

1. Jun 8, 2026 Clinical update

   NER1006-01/2025 — Phase 3

View all clinical trial activity →

• What is Norgine?

  Norgine Pty is a pharma organization headquartered in Amsterdam, AU. Primary therapeutic focus areas include Colonic disease. NovaPharmaNews links 1 clinical program(s), 2 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO s

• Is Norgine publicly traded?

  Norgine appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Norgine develop or market?

  We link 3 drug profile(s) where Norgine is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/norgine-b-v#company-drugs.

• What are the latest developments for Norgine?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Norgine focus on?

  Norgine focuses on Colonic disease based on our analysis of their pipeline programs and drug development activities.